Photodynamic diagnosis reinforces the prediction for the prognosis of castration resistant prostate cancer

2014 Fiscal Year Final Research Report

• Project/Area Number: 25861445
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Nara Medical University
• Principal Investigator: ANAI Satoshi 奈良県立医科大学, 医学部, 助教 (70526699)
• Project Period (FY): 2013-04-01 – 2015-03-31
• Keywords: 去勢抵抗性前立腺癌 / 低侵襲検査 / 蛍光細胞診 / 尿細胞診 / 予後予測 / 治療効果予測 / PTEN

Outline of Final Research Achievements

Castration Resistant Prostate Cancer (CRPC) comprises a large portion of cause of death among prostate cancer patients. In about 30% of CRPC cases, Prostate Specific Antigen (PSA), the most reliable marker for diagnosis and assessment of the therapeutic value, is not associated with the disease progression. As a result, developing a useful treatment in terms of the predictor of therapeutic value and prognosis was a pressing issue for us to be resolved.
We have been developing the photodynamic diagnosis (PDD) using patients’ urine for the detection of prostate cancer. In this study, PDD is applied to the diagnosis for CRPC. Namely, Protoporphyrin IX (PpIX) can be detected in CRPC patients’ urine and the intensity of PpIX can be quantified by the spectrophotometer. Moreover, the deletion of PTEN, which is known as the biomarker for the curative therapy such as radiation and operation, can be detected in CRPC patients’ urine by FISH. About 40 % of CPRC appeared PTEN deletion by FISH.

Free Research Field

泌尿器腫瘍学